Mon. 22 Apr 2024, 7:08am ET
Benzinga
News
Company plans to initiate SERENITY At-Home pivotal Phase 3 safety trial with 120 mcg dose following recent meeting with FDA
No FDA-approved therapies for acute treatment of agitation associated with bipolar disorders or schizophrenia in the home setting